Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials.
作者信息
Van Dyck Christopher H, O'Dell Ryan S, Mecca Adam P
机构信息
Department of Psychiatry Alzheimer's Disease Research Unit, Yale School of Medicine New Haven Connecticut USA.
出版信息
Alzheimers Dement (N Y). 2023 May 11;9(2):e12388. doi: 10.1002/trc2.12388. eCollection 2023 Apr-Jun.
Abstract
摘要
相似文献
1
Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials.阿尔茨海默病临床试验临床结局评估中的疾病严重程度及最小临床重要差异
Alzheimers Dement (N Y). 2023 May 11;9(2):e12388. doi: 10.1002/trc2.12388. eCollection 2023 Apr-Jun.
2
Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials.阿尔茨海默病临床试验临床结局评估中的疾病严重程度及最小临床重要差异
Alzheimers Dement (N Y). 2019 Aug 2;5:354-363. doi: 10.1016/j.trci.2019.06.005. eCollection 2019.
3
Establishing Clinically Meaningful Change on Outcome Assessments Frequently Used in Trials of Mild Cognitive Impairment Due to Alzheimer's Disease.确立阿尔茨海默病导致轻度认知障碍临床试验中常用结局评估的临床有意义变化。
J Prev Alzheimers Dis. 2023;10(1):9-18. doi: 10.14283/jpad.2022.102.
4
Integrated Alzheimer's Disease Rating Scale: Clinically meaningful change estimates.综合阿尔茨海默病评定量表：具有临床意义的变化估计值。
Alzheimers Dement (N Y). 2022 Jun 6;8(1):e12312. doi: 10.1002/trc2.12312. eCollection 2022.
5
Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study).评估新型胰高血糖素样肽-1类似物利拉鲁肽对阿尔茨海默病的影响：一项随机对照试验的研究方案（ELAD研究）。
Trials. 2019 Apr 3;20(1):191. doi: 10.1186/s13063-019-3259-x.
6
Performance-based and Observational Assessments in Clinical Trials Across the Alzheimer's Disease Spectrum.阿尔茨海默病谱系临床试验中的基于表现和观察性评估
Innov Clin Neurosci. 2017 Feb 1;14(1-2):30-39. eCollection 2017 Jan-Feb.
7
The need to show minimum clinically important differences in Alzheimer's disease trials.在阿尔茨海默病临床试验中需要显示最小临床重要差异。
Lancet Psychiatry. 2021 Nov;8(11):1013-1016. doi: 10.1016/S2215-0366(21)00197-8. Epub 2021 Jun 1.
8
Technical Review of Clinical Outcomes Assessments Across the Continuum of Alzheimer's Disease.阿尔茨海默病全病程临床结局评估的技术综述
Neurol Ther. 2023 Apr;12(2):571-595. doi: 10.1007/s40120-023-00443-2. Epub 2023 Feb 15.
9
Clinical importance in Alzheimer's disease: effects of anchor agreement and disease severity.阿尔茨海默病中的临床重要性：锚定一致性和疾病严重程度的影响。
Aging Clin Exp Res. 2024 Jan 24;36(1):5. doi: 10.1007/s40520-023-02643-0.
10
Outcomes Assessment in Clinical Trials of Alzheimer's Disease and its Precursors: Readying for Short-term and Long-term Clinical Trial Needs.阿尔茨海默病及其前驱症状临床试验的结果评估：为短期和长期临床试验需求做准备。
Innov Clin Neurosci. 2017 Feb 1;14(1-2):22-29. eCollection 2017 Jan-Feb.
引用本文的文献
1
Disentangling minimum clinically important difference for an individual and a population in the treatment of Alzheimer's disease.厘清阿尔茨海默病治疗中个体和群体的最小临床重要差异。
Alzheimers Dement (N Y). 2025 May 13;11(2):e70093. doi: 10.1002/trc2.70093. eCollection 2025 Apr-Jun.
2
Measuring time saved in Alzheimer's disease: What is a meaningful slowing of progression?衡量阿尔茨海默病中节省的时间：有意义的疾病进展减缓是怎样的？
Alzheimers Dement (N Y). 2025 Apr 11;11(2):e70081. doi: 10.1002/trc2.70081. eCollection 2025 Apr-Jun.
3
Avoiding causal fraud in the evaluation of clinical benefits of treatments for Alzheimer's disease.在评估阿尔茨海默病治疗的临床益处时避免因果欺诈。
Alzheimers Dement. 2025 Feb;21(2):e14457. doi: 10.1002/alz.14457. Epub 2025 Jan 27.
4
Perspectives on the clinical use of anti-amyloid therapy for the treatment of Alzheimer's disease: Insights from the fields of cancer, rheumatology, and neurology.抗淀粉样蛋白疗法治疗阿尔茨海默病的临床应用前景：来自癌症、风湿病学和神经病学领域的见解
Alzheimers Dement (N Y). 2024 Sep 18;10(3):e12500. doi: 10.1002/trc2.12500. eCollection 2024 Jul-Sep.
5
Alzheimer's Amyloid Hypothesis and Antibody Therapy: Melting Glaciers?阿尔茨海默病淀粉样蛋白假说和抗体疗法：冰川消融？
Int J Mol Sci. 2024 Mar 31;25(7):3892. doi: 10.3390/ijms25073892.
本文引用的文献
1
Expectations and clinical meaningfulness of randomized controlled trials.随机对照试验的预期和临床意义。
Alzheimers Dement. 2023 Jun;19(6):2730-2736. doi: 10.1002/alz.12959. Epub 2023 Feb 7.
2
Lecanemab for Alzheimer's disease.用于治疗阿尔茨海默病的lecanemab
BMJ. 2022 Dec 19;379:o3010. doi: 10.1136/bmj.o3010.
3
Lecanemab in Early Alzheimer's Disease.早期阿尔茨海默病中的lecanemab
N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29.
4
The need to show minimum clinically important differences in Alzheimer's disease trials.在阿尔茨海默病临床试验中需要显示最小临床重要差异。
Lancet Psychiatry. 2021 Nov;8(11):1013-1016. doi: 10.1016/S2215-0366(21)00197-8. Epub 2021 Jun 1.
5
Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials.阿尔茨海默病临床试验临床结局评估中的疾病严重程度及最小临床重要差异
Alzheimers Dement (N Y). 2019 Aug 2;5:354-363. doi: 10.1016/j.trci.2019.06.005. eCollection 2019.
6
Bridging the gap: using triangulation methodology to estimate minimal clinically important differences (MCIDs).弥合差距：运用三角测量法估算最小临床重要差异（MCIDs）。
COPD. 2005 Mar;2(1):157-65. doi: 10.1081/copd-200050508.
Zotero 插件